share_log

Nuvalent Presents New Preclinical Data For HER2-Selective Inhibitor, NVL-330, And ROS1-Selective Inhibitor, Zidesamtinib, At AACR Annual Meeting 2024

Moomoo 24/7 ·  Apr 8 16:36

Preclinical data continue to support NVL-330's broad activity against HER2 oncogenic alterations, selectivity over wild-type EGFR, and differentiated brain-penetrant profile

Zidesamtinib shown to be effective at suppressing on-target ROS1 resistance mutations in preclinical mutagenesis screens

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment